vTv Therapeutics Inc
VTVT29.020USD
-1.990-6.42%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
114.28M시가총액
손실P/E TTM
자세한 내용은 vTv Therapeutics Inc 회사
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
vTv Therapeutics Inc 정보
종목 코드 VTVT
회사 이름vTv Therapeutics Inc
상장일Jul 30, 2015
CEOSekhri (Paul Jai)
직원 수23
유형Ordinary Share
회계 연도 종료Jul 30
주소3980 Premier Dr
도시HIGH POINT
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호27265
전화13368410300
웹사이트https://vtvtherapeutics.com/
종목 코드 VTVT
상장일Jul 30, 2015
CEOSekhri (Paul Jai)
vTv Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
-24062.00%
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
2.15K
+2146.00%
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
1.83K
+1833.00%
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
Mr. Burns Mcclellan
Mr. Burns Mcclellan
Investor Relations
Investor Relations
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
-2251.00%
Mr. Daniel (Dan) Spiegelman
Mr. Daniel (Dan) Spiegelman
Director
Director
--
--
Dr. Michael Tung, M.D.
Dr. Michael Tung, M.D.
Executive Vice President, Chief Financial Officer
Executive Vice President, Chief Financial Officer
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
-24062.00%
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
2.15K
+2146.00%
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
1.83K
+1833.00%
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
Mr. Burns Mcclellan
Mr. Burns Mcclellan
Investor Relations
Investor Relations
--
--
수익 분석
FY2023
기업이 아직 관련 데이터를 공개하지 않았습니다.
지역별USD
이름
수익
비율
United States
0.00
0.00%
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Fri, Feb 6
마지막 업데이트: Fri, Feb 6
주주
주주 유형
주주
주주
비율
MacAndrews & Forbes Holdings, Inc.
23.18%
Samsara BioCapital, LLC
7.58%
Trails Edge Capital Partners LP
5.87%
Fidelity Management & Research Company LLC
4.90%
Invus Public Equities Advisors, LLC
4.14%
기타
54.33%
주주
주주
비율
MacAndrews & Forbes Holdings, Inc.
23.18%
Samsara BioCapital, LLC
7.58%
Trails Edge Capital Partners LP
5.87%
Fidelity Management & Research Company LLC
4.90%
Invus Public Equities Advisors, LLC
4.14%
기타
54.33%
주주 유형
주주
비율
Holding Company
23.18%
Investment Advisor
17.37%
Venture Capital
7.58%
Hedge Fund
4.34%
Investment Advisor/Hedge Fund
0.75%
Individual Investor
0.42%
기타
46.35%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
44
1.18M
30.04%
+255.03K
2025Q3
47
1.15M
29.13%
+562.26K
2025Q2
54
1.51M
57.66%
-17.51K
2025Q1
53
1.53M
60.03%
+1.63K
2024Q4
55
1.51M
61.92%
-7.51K
2024Q3
55
1.49M
61.31%
+181.69K
2024Q2
53
1.29M
53.13%
+308.00
2024Q1
64
1.68M
72.07%
+129.32K
2023Q4
64
1.40M
68.78%
-52.49K
2023Q3
72
1.41M
69.35%
-49.61K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
MacAndrews & Forbes Holdings, Inc.
912.98K
23.18%
--
--
Apr 01, 2025
Samsara BioCapital, LLC
298.50K
7.58%
-75.97K
-20.29%
Dec 08, 2025
Trails Edge Capital Partners LP
231.00K
5.87%
+231.00K
--
Aug 29, 2025
Fidelity Management & Research Company LLC
192.89K
4.9%
+14.69K
+8.24%
Sep 30, 2025
Invus Public Equities Advisors, LLC
163.00K
4.14%
--
--
Sep 30, 2025
Baker Bros. Advisors LP
148.31K
3.77%
+51.00K
+52.41%
Sep 30, 2025
The Vanguard Group, Inc.
46.99K
1.19%
+3.81K
+8.84%
Sep 30, 2025
Geode Capital Management, L.L.C.
15.30K
0.39%
+2.43K
+18.90%
Sep 30, 2025
Northern Trust Investments, Inc.
14.07K
0.36%
-1.22K
-7.95%
Sep 30, 2025
Millennium Management LLC
12.94K
0.33%
-2.11K
-14.01%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Micro-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
비율0.01%
iShares Core S&P Total U.S. Stock Market ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
날짜
배당락일
유형
비율
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
